In vitro-in vivo correlation (IVIVC) is a predictive mathematical tool that describes the relationship between an in vitro property of a drug dosage form and an in vivo pharmacokinetic response. Drug developers frequently use this approach to waive the requirement to show in vivo bioavailability or bioequivalence.
In theory, developing an IVIVC is straightforward for immediate release oral formulations. Delayed release drug formulations deliver a drug with a delay after its administration. IVIVC then becomes a real challenge. This webinar showed how to use a time correction factor to establish a meaningful IVIVC for delayed release formulation drugs.
About Our Speaker
Jean-Michel Cardot is a professor and head of the Department of Biopharmaceutics and Pharmaceutical Technology at the Auvergne University in France. Prior to coming to Auvergne University, he worked in the pharmaceutical industry for 15 years. Prof. Cardot earned degrees in pharmacy (PharmD), a Masters in Bio-pharmaceutical, Statistical sciences and Pharmacokinetics, and a doctorate in pharmaceutical sciences from Auvergne University. His research interests include biopharmaceutical development of drugs, in vitro dissolution, and in vivo bioequivalence and in vitro-in vivo correlation.